Oral pharmaceutical formulation comprising cannabinoids and poloxamer
OwnerJitinder WILKHU, Johan BENDERinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The formulation comprises a combination of at least two cannabinoids. The first cannabinoid is selected from the group consisting of tetrahydrocannabinol (THC) and analogues thereof; and the second cannabinoid is selected from the group consisting of cannabidiol (CBD) and analogues thereof.
Claims30
An oral pharmaceutical formulation comprising a first cannabinoid selected from the group consisting of tetrahydrocannabinol (THC) and analogues thereof;
- a second cannabinoid selected from the group consisting of cannabidiol (CBD) and analogues thereof;
- at least one poloxamer;
- and a solvent, wherein the solvent is defined according to formula (I)
- wherein R1 and R2 are independently selected from hydrogen, C(O)CH3, OH, C(O)CH3, CH2OH and C(O)OCH2CH3;
- R3 is independently selected from CH3, CH2OH, OH, CH2OC(O)CH3 and CH2C(O)CH2CH3;
- and R4 is independently selected from hydrogen and C(O)OCH2CH3.
27-30. (canceled)
33-34. (canceled)
Dependencies are inferred from the claim text.